Method for monitoring the treatment effect of Myeloproliferative neoplasms
- researcher's name
- affiliation
- research field
-
Biofunction/Bioprocess,Environmental engineering and reduction of environmental burden,Applied microbiology,Bacteriology (including mycology)
- keyword
-
background
● JAK2 V617F point mutation is detected as one of the driver mutations of myeloproliferative neoplasms (MPNs)
● High JAK2 V617F allele burden associates with the poor prognosis of MPNs
● Clinical examination technique to estimate the therapeutic effects is required
● High JAK2 V617F allele burden associates with the poor prognosis of MPNs
● Clinical examination technique to estimate the therapeutic effects is required
summary
● Usage of the fluorescence-dye-labeled probe exhibiting fluorescent intensity as a function of the amount of V617F allele
● JAK2 V617F allele burden can be quantified equivalent to the results by next- generation sequencing (NGS)
● Available for the monitoring of slight increase/decrease of V617F allele burden
● JAK2 V617F allele burden can be quantified equivalent to the results by next- generation sequencing (NGS)
● Available for the monitoring of slight increase/decrease of V617F allele burden
predominance
● NGS-compatible determination precision with simple and cost-effective workflow
● Precise quantification independent with the input gDNA amount
● Utilized to determine the therapeutic effect
● Precise quantification independent with the input gDNA amount
● Utilized to determine the therapeutic effect
application/development
● Clinical examination
● Prognosis predicting
● Drug screening
● Prognosis predicting
● Drug screening
same researcher's seeds
posted:
2019/10/21